<p>This is a summary of the European public assessment report (EPAR) for Lyrica. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lyrica.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p><strong>Neuropathic pain</strong></p> <ul> <li>Lyrica is indicated for the treatment of peripheral and central neuropathic pain in adults.</li> </ul> <p><strong>Epilepsy</strong></p> <ul> <li>Lyrica is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.</li> </ul> <p><strong>Generalised anxiety disorder</strong></p> <ul> <li>Lyrica is indicated for the treatment of generalised anxiety disorder (GAD) in adults.</li> </ul> </div>
Therapeutic Area (MeSH)
ATC Code
N02BF02
ATC Item
N/A
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| pregabalin | N/A | pregabalin |
EMA Name
Lyrica
Medicine Name
Lyrica
Aliases
N/ANo risk management plan link.
